165 related articles for article (PubMed ID: 25410665)
1. Growth patterns in children with mucopolysaccharidosis I and II.
Różdżyńska-Świątkowska A; Jurecka A; Cieślik J; Tylki-Szymańska A
World J Pediatr; 2015 Aug; 11(3):226-31. PubMed ID: 25410665
[TBL] [Abstract][Full Text] [Related]
2. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.
Rozdzynska A; Tylki-Szymanska A; Jurecka A; Cieslik J
Acta Paediatr; 2011 Mar; 100(3):456-60. PubMed ID: 20950410
[TBL] [Abstract][Full Text] [Related]
3. Review of mucopolysaccharidosis diseases at the Queen Sirikit National Institute of Child Health in the past 15 years.
Kuptanon C; Pangkanon S
J Med Assoc Thai; 2014 Jun; 97 Suppl 6():S142-6. PubMed ID: 25391186
[TBL] [Abstract][Full Text] [Related]
4. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
5. Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.
Różdżyńska-Świątkowska A; Zielińska A; Tylki-Szymańska A
Orphanet J Rare Dis; 2022 Sep; 17(1):339. PubMed ID: 36064607
[TBL] [Abstract][Full Text] [Related]
6. Anthropometric characteristics of four Polish children with mucopolysaccharidosis.
Perenc L
BMC Res Notes; 2013 Jul; 6():246. PubMed ID: 23815875
[TBL] [Abstract][Full Text] [Related]
7. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry.
Viskochil D; Clarke LA; Bay L; Keenan H; Muenzer J; Guffon N
Am J Med Genet A; 2019 Dec; 179(12):2425-2432. PubMed ID: 31639289
[TBL] [Abstract][Full Text] [Related]
8. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB
Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037
[TBL] [Abstract][Full Text] [Related]
9. Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.
Taylor NE; Dengel DR; Lund TC; Rudser KD; Orchard PJ; Steinberger J; Whitley CB; Polgreen LE
J Pediatr Rehabil Med; 2014; 7(4):353-60. PubMed ID: 25547887
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center.
Moreira GA; Kyosen SO; Patti CL; Martins AM; Tufik S
Sleep Breath; 2014 Dec; 18(4):791-7. PubMed ID: 24705807
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of physical development of children and adolescents. Part I. Infants and children up to 5 years--national reference values or WHO standards?].
Oblacińska A; Jodkowska M; Mikiel-Kostyra K; Palczewska I
Med Wieku Rozwoj; 2010; 14(2):95-100. PubMed ID: 20919459
[TBL] [Abstract][Full Text] [Related]
12. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.
Kuiper GA; Meijer OLM; Langereis EJ; Wijburg FA
Orphanet J Rare Dis; 2018 Jan; 13(1):2. PubMed ID: 29310675
[TBL] [Abstract][Full Text] [Related]
13. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
[TBL] [Abstract][Full Text] [Related]
14. Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III).
Muschol NM; Pape D; Kossow K; Ullrich K; Arash-Kaps L; Hennermann JB; Stücker R; Breyer SR
Orphanet J Rare Dis; 2019 May; 14(1):93. PubMed ID: 31046785
[TBL] [Abstract][Full Text] [Related]
15. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status.
Marucha J; Jurecka A; Syczewska M; Różdżyńska-Świątkowska A; Tylki-Szymańska A
Acta Paediatr; 2012 Apr; 101(4):e183-8. PubMed ID: 22077147
[TBL] [Abstract][Full Text] [Related]
16. Spectral domain optical coherence tomography imaging of mucopolysaccharidoses I, II, and VI A.
Seok S; Lyu IJ; Park KA; Oh SY
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2111-9. PubMed ID: 25690978
[TBL] [Abstract][Full Text] [Related]
17. Ultrasonographic Features of Hip Joints in Mucopolysaccharidoses Type I and II.
Żuber Z; Jurecka A; Różdżyńska-Świątkowska A; Migas-Majoch A; Lembas A; Kieć-Wilk B; Tylki-Szymańska A
PLoS One; 2015; 10(4):e0123792. PubMed ID: 25922936
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
[TBL] [Abstract][Full Text] [Related]
19. [Jena longitudinal study of the growth of 0-3 year old children. 2: Percentile curves for body height, body weight, height related weight and growth rate].
Hesse V; Bernhardt I; Hofmann A; Kunath H; Hesse G
Padiatr Grenzgeb; 1991; 30(3):223-35. PubMed ID: 2067872
[TBL] [Abstract][Full Text] [Related]
20. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.
Yund B; Rudser K; Ahmed A; Kovac V; Nestrasil I; Raiman J; Mamak E; Harmatz P; Steiner R; Lau H; Vekaria P; Wozniak JR; Lim KO; Delaney K; Whitley C; Shapiro EG
Mol Genet Metab; 2015 Feb; 114(2):170-7. PubMed ID: 25541100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
